active long
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Negative news is always quicker to be aired. Although this article contains Anavex's reasoning for coming up short on the one endpoint it is one of several on Biotech websites that has carried the negative news. It seems they much quicker to report negative rather than positive Anavex progress. The PR release just prior to the JPM presupposes, as some have said, that CM has some very optimistic words for the attendees.
https://www.biospace.com/article/anavex-s-stock-nosedives-after-posting-trial-results-for-rett-syndrome/?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsmi=288627796&_hsenc=p2ANqtz-_izMh-Ol2xy047YgqLMbpm73LKB1NRFmFCgQY5v1uyW1bwLh4wgXAOeinYQaE3_8x-7tk8jeGSBrFVIH15Ov8ksa7fNg&utm_content=288627796&utm_source=hs_email
Frrol....if Biogen can maneuver the FDA to accept Aducanumab with little efficacy for Alzheimer's but for reducing amyloid plaque and the panel of experts almost unanimously giving it a "thumps down"....then we have a good opportunity to get 2-73 approved with a little adjustment. The young/older Rett's girls will thank us in the future for standing by their side!
May God bless all of you my fellow posters in 2024 and may He allow our science to treat those who suffer in the world around us very soon!
Kund, There is no published list of attendees and the agenda is available only to official attendees.....what that means is...we don't know about Anavex's attendance!
This brings to mind Merck which has developed and combined with so many other companies the drug "Keytruda". It is a wonder drug in the cancer world and has seen multiple applications aiding possible millions of cancer suffers!!!
Badger....with all the possible uses for 2-73, who can but believe that Anavex has been approached by a big Pharma that wants to be at the ground floor of bringing this drug goldmine to market. This is more than likely a factor in the timing of particular data release and future commercialization plans. We will see this evolve shortly in 2024. This is going to be a big year for those of us that have been soooo patient!!!!!
Maui and Joe....my heart goes out to you and your familys. Alzheimer's is such a vicious disease since it's effects are not only on the individual but their loved ones for years at a time. It's slow degradation of your relative has to be torture. The slow pace of the development of effective drugs to prevent, treat and cure the disease and the lack of positive national resolve to assist biotechs in that goal is frankly not believable. The FDA, EMA, TGA and other national health agencies have to move forward with haste as they have done against cancer. Maybe if the disease attacks the family of one of the leaders of the FDA or Congress we'll see the needed emphasis!
In the meantime my prayers will be for you!
William, good synopsis of Cerevel and comparison with Anavex. I think it is important to note that CERE is over 88% institutionally owned and advice(?) from those institutions may have had weight on the decision of the buyout since the institutions have a lot shorter expectation of ROI than other shareholders. Below is an article about J&J neuroscience acquisitions and future plans....another possible partner?
https://www.fiercebiotech.com/biotech/johnson-and-johnson-outlines-bullish-pipeline-goals-neuroscience-victories-become-paramount
Investment data seems very positive today. According to Yahoo Finance the Institutional Ownership as of last quarter is about 34% with the big three: Bklackrock, Vanguard and State Street owning about 20%. All Performance Outlooks (Short-Mid-Long Term) are "Bullish". Good assessment as we head into the end of the year!
Boi568....agree with your assessment. It would be the correct interpretation and it would follow that the final two words of the sentence are "as well."
An article like this about 2-73's efficacy in Rett Syndrome patients will be helpful once approved.
----
https://www.biospace.com/article/first-rett-treatment-offers-hope-to-morell-family-at-thanksgiving-/?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsmi=283639026&_hsenc=p2ANqtz-_Hvg4U6czZeP2BwhrtPeuI0ik-VPehvDghaCIsK1pPjiQS7Zmire9UyLjoJ6e7h0OHMO5HCyZpItsxtNgX9cUR1I6DJg&utm_content=283639026&utm_source=hs_email
DTRT, multiple sources if you are doing your dd.
Not a good market day for our competitors...SAVA -.23$, ANVS -.29$, BIIB -14.00$.....good for possible partners MRK +.40$, Lilly +19$!
Mike. what is true in the market is not necessarily true in corporate history....and the history of many large successful companies today began with their "humble" beginnings!
I've said this before, but it needs to be pointed out again because of the crowd's impatience. Anavex is not only working with the FDA but the similar agencies in Australia, Canada, The UK and EU countries. That would be an immense work load for big phamas like Merck, Lilly, and others, but almost insurmountable for a small biotech like Anavex. This is the imperative for a partnership which IMO is forming right now!
Investor.....that is sales out of the gate. The question is which drugs are more effective and will be paid for by worldwide health systems in the coming years. And then there is 3-71!
Steady
It is forecast sales of course.
Eisai is forecasting 10Million Yen($66Mil$) from Lequimbi by Mar 2024 and Biogen has its forecast out tomorrow and we'll see what sales are expected for Aducanumab. Approval of 2-73 in 2024 will be quite a spoiler on those "amyloid" drugs sale there after, "IMO".
https://finance.yahoo.com/news/eisai-expects-alzheimers-drug-rake-141040274.html
This MJFF test should be completed or near completion. Most of its objectives i.e. safety and efficacy should have already been demonstrated in the Parkinson's Dementia trial. Why this intermediate study is anybody's guess. Think we will be going to P3 soon.
---
https://www.michaeljfox.org/grant/evaluation-anavex2-73-blarcamesine-participants-parkinsons-disease
Nidan....great news for Alzheimer's.....MJFF is very optimistic about their progress in the Parkinson's world with their resent " biomarker" progress which will identify the disease sooner and of course identify efficacy of treatments. As we know, Anavex 2-73 is one of the positive drugs going thru their funded research following a successful P2 for Parkinson's Dementia. The clouds are opening up on Anavex's future success!!
------
https://www.michaeljfox.org/news/michael-j-fox-parkinsons-science-momentum-2023-stat-summit-we-dont-want-be-celebrated-we-want?em_cid=mc-a1bHq00000AeQZ0
Steady.....maybe he's being offered a deal that he can't refuse.
All the Alzheimer's companies AVXL, SAVA, ANVS, BIIB are down today. Anavex has been quiet for a month which has been suggested in the past as a quiet period before announcement of a partnership. One would suppose that if there is major progress that a new partner would want to coordinate/prepare for that announcement. Also, other insiders would be accumulating at this low price but not many selling. An optimist assessment!
The Alzheimer's - Parkinson's connection bodes well for our stock.
https://www.biospace.com/article/parkinson-s-research-buoyed-by-advances-in-alzheimer-s-/?utm_campaign=Newsletter | GenePool&utm_medium=email&_hsmi=276776989&_hsenc=p2ANqtz-9li1HE67iKAioEicEnOt0i8q39g00-BIRdKqDMFeb6LMabAoWSiXHou87RMSMGIoDqHMJuMfNCD-iNqdQf6_4j38_onA&utm_content=276776989&utm_source=hs_email
3 million shares traded hands on Friday......3 million out of unsure hands and 3 million into sure hands!
Badger...saw the same positive article in "Biospace". Despite mentioning AF( don't know how a hack like AF gets mentioned in scientific press), the article was good high level coverage of Anavex. So why is the market this morning reacting negatively? Gives a lot of credence to the elements, may they be MM or controlling entities such as Blackrock, State Street, Vanguard that want to keep the price low while accumulating. Not the way American commerce should conduct itself....the opinion of a private investor!
Not a good day for Biotechs....we did better than most holding our own. The quietness on our front I would guess is leading to Retts data or partnership announcement soon!
Nidan.....my prayers for you and your family.
Talon
Investor....a great video "Mitochondria - The key to Disease and Mental Health" points to the Mitochondria as the energy suppliers of our bodies. The prime example of limiting or cutting of the blood supply to our brain causes us to faint or in the worst case die. It is absolutely evident that if you degrade or cease the operation of mitochondria to any part of the body you degrade that part of the body's function. As Dr. Picard points out, for the mitochondria to function properly the body must have activity, proper diet and positive life outlook(attitude). All three of these aspects, for most of us, degrade with age and certainly that seems to correlate with the advent of Alzheimers and other dementia. And again, many older people are mentally vital while exhibiting adherence to the three factors....and maybe with having a high level of alpha beta plaque and tau. Thus Dr. Picard emphasis on keeping the mitochondria healthy and Anavex 2-73's apparent facilitating that.
This line of research is encouraging and positive for 2-73 and 3-71's MOA. It will optimistically lead to acceptance of our drugs replacement or repair of the bodies mitochondria and subsequent wide area health application!
Thanks, Investor for this excellent point of DD.
Badger....along with new biomarkers in your article on Alzheimer's diagnosis the "Shake it Up" organization in Australia has just announced Duke University's research into a blood centered biomarker for Parkinson's. Researchers have discovered that in people who have Parkinson's there is damage within their brain mitochondria. Just like Alzheimer's the S1 repair mechanism should show up in people who take 2-73. The MJFF working thru "Shake it up Australia" is conducting a test prior to further trials where this biomarker should show that 2-73 is repairing the mitochondria.
---------
https://shakeitup.org.au/researchers-find-potential-new-blood-test-for-detecting-parkinsons/?apcid=006281de3d955e6458b33100&utm_campaign=september-newsletter-edm&utm_content=september-newsletter-edm&utm_medium=email&utm_source=ortto
Positive points Falconer. But we are talking about the stock market evaluation of our companies and who knows Blackrock's investment in major health companies which by the way make $millions on Alzheimer's patient care. And then there is the politics of Federal Agencies. Misslings plans are to get FDA approval as a step toward international approval 2-73. Maybe this will change with a major Pharma partner. In any case, I think Blackrock can, will or is a major player in the progress of our stock.
Boi.....Blackrock owns $3.7 Billion of Biogen stock and $46 Million of Anavex. Would it be logical that someone on Finks staff is looking at the competition of the two companies over their Alzheimer's drugs...and maybe their MS drugs in the future?
Tred....you're very preceptive. Larry Fink's Blackrock controls over $10 Trillion of the market and is a major controlling investor in most of the effective Pharmas and Biotechs. As I said before, his investment in Biogen is considerably more than Anavex, so you know which way he will lean as 2-73 has become an Alzheimer's competitor. See what Porter Stansberry says about about he and Michael Bloomberg and their "stakeholder capitalism" (ESG).
We're posting like the teacher is not in the room. Settle down, stop the name calling. Consider others with the respect as you would have them respect you.
Wonder if AI drug development will take the nominal 10 years and $10Mil that traditional drug development has taken. What will the FDA do to accelerate critical drugs to the market?
--------
https://www.foxnews.com/health/new-ai-generated-covid-drug-enters-phase-i-clinical-trials-effective-variants
Tootall.....an excellent empirical statement about stock investing, and I grant you the majority of us are amateur investors, so thanks for the advice. But most of us have been invested in Anavex for quite a few years and digested quite a bit of "due diligence". We are not biotech scientists, but the company has a few on staff with good credentials as well as three former FDA Managers. As for "dreamers" look at the number who founded great businesses over the last century and a half! Biotech is all front loaded because drugs are yet to market, but the return is great if successful. Anavex's progress has up to this point has been positive and if it is successful, think of the little girls and the millions of Alzheimer's sufferers who will benefit immeasurably! Hang Tuff.
My assessment of this long trading period in the $7 and 8s is that MM are trying to shake loose individual shareholders shares for the institutions in anticipation of Rett and Alzheimer's good news shortly. As I said before, the big three exhibit steady growth of their share growth. Hang Tuff!
More break throughs on Alzheimer's determination, although these new techniques are mainly meant to use diagnosis of alpha beta plaque and tau as an alternative to PET scans needed by Leqembi. Blood analysis which show other forms of dementia are still in development.
https://www.biospace.com/article/new-biomarker-tests-aid-the-quick-and-accurate-diagnosis-of-alzheimer-s-disease/?utm_campaign=Newsletter |
Bas, Investor......truce please. You both are presenting valid arguments for your positions and it is filling up the board with its volume in the vacuum of releases of progress updates from our company. It is endemic that a small company is slow to respond when pursuing four or more major trials, but it is also clear that three former FDA managers are talking to former workmates within the Agency on crucial moves necessary to provide a successful NDAs for the trials. More than likely, the FDA is a little "gun shy" with the response to the approval of the Biogen and Eisai"s drugs and are demanding more in the way of efficacy and less in the way of side effects. And, it is just good business to acquire the voucher thru Rett Syndrome.
So lighten up on each other, appreciate the positive and save the end of your fingers!
Tred....the complexity and scope of our trials over numerous countries and national health agencies give reason for the process speed of our "little" biotech. Sequencing Rett Syndrome ahead of Alzheimers to possibly collect the voucher valued probably in the $ Millions also has effected the time factor!. If everyone of us investors would notice that the big three institutional entities, Blackrock, State Street and Vanguard have increased their quarterly share count regularly, we would sleep easier.
Breathe easy my Brother.
Talon
Badger....one would think that Anavex's three former FDA managers would be cooperating with their former work associates at the Agency to have them pursue 2-73 for Rett Syndrome, Fragile X and other rare diseases. The optimist/pragmatist in me says this is happening at this very moment.